Search

Your search keyword '"Schouten, Harry C."' showing total 18 results
Start Over Author "Schouten, Harry C." Publisher wiley
18 results on '"Schouten, Harry C."'

1. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Author

Harrison, Claire N., primary, Schaap, Nicolaas, additional, Vannucchi, Alessandro M., additional, Kiladjian, Jean‐Jacques, additional, Jourdan, Eric, additional, Silver, Richard T., additional, Schouten, Harry C., additional, Passamonti, Francesco, additional, Zweegman, Sonja, additional, Talpaz, Moshe, additional, Verstovsek, Srdan, additional, Rose, Shelonitda, additional, Shen, Juan, additional, Berry, Tymara, additional, Brownstein, Carrie, additional, and Mesa, Ruben A., additional

Published
2020
Full Text
View/download PDF

2. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission

Author

Poiré, Xavier, primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Maertens, Johan, additional, Deconinck, Eric, additional, Forcade, Edouard, additional, Rambaldi, Alessandro, additional, Baerlocher, Gabriela M., additional, Zuckerman, Tsila, additional, Volin, Liisa, additional, Schouten, Harry C., additional, Ifrah, Norbert, additional, Mohty, Mohamad, additional, Esteve, Jordi, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

3. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Author

Smith, Sonali M., primary, Godfrey, James, additional, Ahn, Kwang Woo, additional, DiGilio, Alyssa, additional, Ahmed, Sairah, additional, Agrawal, Vaibhav, additional, Bachanova, Veronika, additional, Bacher, Ulrike, additional, Bashey, Asad, additional, Bolaños‐Meade, Javier, additional, Cairo, Mitchell, additional, Chen, Andy, additional, Chhabra, Saurabh, additional, Copelan, Edward, additional, Dahi, Parastoo B., additional, Aljurf, Mahmoud, additional, Farooq, Umar, additional, Ganguly, Siddhartha, additional, Hertzberg, Mark, additional, Holmberg, Leona, additional, Inwards, David, additional, Kanate, Abraham S., additional, Karmali, Reem, additional, Kenkre, Vaishalee P., additional, Kharfan‐Dabaja, Mohamed A., additional, Klein, Andreas, additional, Lazarus, Hillard M., additional, Mei, Matthew, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Ramakrishnan Geethakumari, Praveen, additional, Saad, Ayman, additional, Savani, Bipin N., additional, Schouten, Harry C., additional, Shah, Nirav, additional, Urbano‐Ispizua, Alvaro, additional, Vij, Ravi, additional, Vose, Julie, additional, Sureda, Anna, additional, and Hamadani, Mehdi, additional

Published
2018
Full Text
View/download PDF

6. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Author

Doorduijn, Jeanette K., primary, van Imhoff, Gustaaf W., additional, van der Holt, Bronno, additional, Schouten, Harry C., additional, Schaafsma, Martijn R., additional, MacKenzie, Marius A., additional, Baars, Joke W., additional, Kersten, Marie José, additional, Lugtenburg, Pieternella J., additional, van den Bent, Martin J., additional, Enting, Roelien H., additional, Spoelstra, Fokje M., additional, Poortmans, Philip, additional, and Bromberg, Jacoline E.C., additional

Published
2016
Full Text
View/download PDF

7. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

Author

Deol, Abhinav, primary, Sengsayadeth, Salyka, additional, Ahn, Kwang Woo, additional, Wang, Hai-Lin, additional, Aljurf, Mahmoud, additional, Antin, Joseph Harry, additional, Battiwalla, Minoo, additional, Bornhauser, Martin, additional, Cahn, Jean-Yves, additional, Camitta, Bruce, additional, Chen, Yi-Bin, additional, Cutler, Corey S., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hamadani, Mehdi, additional, Inamoto, Yoshihiro, additional, Jagasia, Madan, additional, Kamble, Rammurti, additional, Koreth, John, additional, Lazarus, Hillard M., additional, Liesveld, Jane, additional, Litzow, Mark R., additional, Marks, David I., additional, Nishihori, Taiga, additional, Olsson, Richard F., additional, Reshef, Ran, additional, Rowe, Jacob M., additional, Saad, Ayman A., additional, Sabloff, Mitchell, additional, Schouten, Harry C., additional, Shea, Thomas C., additional, Soiffer, Robert J., additional, Uy, Geoffrey L., additional, Waller, Edmond K., additional, Wiernik, Peter H., additional, Wirk, Baldeep, additional, Woolfrey, Ann E., additional, Bunjes, Donald, additional, Devine, Steven, additional, de Lima, Marcos, additional, Sandmaier, Brenda M., additional, Weisdorf, Dan, additional, Khoury, Hanna Jean, additional, and Saber, Wael, additional

Published
2016
Full Text
View/download PDF

8. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of

Author

Yeshurun, Moshe, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Sengeloev, Henrik, additional, Vindelov, Lars, additional, Kuball, Juergen, additional, Chevallier, Patrice, additional, Craddock, Charles, additional, Socie, Gerard, additional, Bilger, Karin, additional, Schouten, Harry C., additional, Fegueux, Nathalie, additional, Goker, Hakan, additional, Maertens, Johan, additional, Bunjes, Donald, additional, Arnold, Renate, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2013
Full Text
View/download PDF

11. Morphologically normal, CD30-negative B-lymphocytes with chromosome aberrations in classical Hodgkin's disease: the progenitor cell of the malignant clone?

Author

Jansen, Maurice P. H. M., primary, Hopman, Anton H. N., additional, Bot, Fredrik J., additional, Haesevoets, Annick, additional, Stevens-Kroef, Marian J. P. L., additional, Arends, Jan Willem, additional, Jox, Andrea, additional, Wolf, J�rgen, additional, Ramaekers, Frans C. S., additional, and Schouten, Harry C., additional

Published
1999
Full Text
View/download PDF

17. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.

Author

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, and Mesa RA

Abstract

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States for treatment of patients with intermediate-2 or high-risk myelofibrosis. The single-arm, phase II JAKARTA2 trial assessed fedratinib 400 mg/d (starting dose) in patients with myelofibrosis previously treated with ruxolitinib. Patient-reported changes in myelofibrosis symptom severity using the modified Myelofibrosis Symptom Assessment Form (MFSAF), and overall HRQoL and functional status using the EORTC QLQ-C30, were evaluated at each cycle. Clinically meaningful changes from baseline HRQoL scores were based on effect sizes. Ninety patients were MFSAF-evaluable. Myelofibrosis symptoms were mild-to-moderate at baseline. Patients showed statistically significant and clinically meaningful improvements in total symptom scores from baseline on the MFSAF at all post baseline visits through the end of cycle 6 (EOC6). Baseline global health status/QoL and functional domain scores on the EORTC QLQ-C30 were meaningfully worse than in the general population. At EOC6, 44% of patients reported clinically meaningful improvements in global health status/QoL, and 30%-53% of patients experienced clinically meaningful improvement in QLQ-C30 functional domains across post baseline timepoints. Over 80% of ongoing patients perceived fedratinib as beneficial on the Patient's Global Impression of Change questionnaire. Fedratinib effects were consistent among prognostically relevant patient subgroups. Patients with myelofibrosis previously treated with ruxolitinib experienced clinically meaningful improvements in myelofibrosis symptom burden, overall HRQoL, and functional status in the first 6 months of fedratinib treatment., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2021
Full Text
View/download PDF

18. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Author

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, and Mohty M

Subjects
Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Cytarabine therapeutic use, Disease-Free Survival, Female, Graft vs Host Disease prevention & control, Humans, Immunosuppressive Agents therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute surgery, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local prevention & control, Neoplasm Recurrence, Local surgery, Retrospective Studies, Transplantation, Homologous methods, Treatment Outcome, Young Adult, Consolidation Chemotherapy methods, Leukemia, Myeloid, Acute therapy, Stem Cell Transplantation methods, Transplantation Conditioning methods
Abstract

Background: The objective of the current study was to investigate the role of postremission consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) for patients with acute myeloid leukemia (AML) in first complete remission (CR1)., Methods: Of the 789 consecutive patients with AML in CR1 who underwent RIC alloSCT from a human leukocyte antigen-matched sibling or matched unrelated donor peripheral stem cell grafts between 2001 and 2010, 591 patients received at least 1 cycle of consolidation chemotherapy and 198 patients did not receive any consolidation chemotherapy before alloSCT. To minimize inherent survival bias in favor of patients who underwent transplant long after achieving CR1, the study focused on 373 patients who underwent transplant within the median time frame between achievement of CR1 and alloSCT (3 months for patients who underwent alloSCT from matched siblings and 4 months for patients who underwent alloSCT from matched unrelated donors). In this subgroup, 151 patients did not receive any consolidation chemotherapy and 222 patients received ≥ 1 consolidation chemotherapy cycle., Results: With a median follow-up of 36 months (range, 2 months-135 months), the 3-year cumulative recurrence incidence (RI) was not significantly different between the groups (36% ± 4% for the group treated without consolidation chemotherapy vs 38% ± 3% for patients who received consolidation chemotherapy; P = .89). In addition, leukemia-free survival was similar between the groups (45% ± 4% and 47% ± 3%, respectively; P = .41). Dose intensity of cytarabine given during consolidation chemotherapy appeared to have no influence on RI. On multivariate analysis, pretransplant consolidation (≥ 1 cycle vs 0 cycles) was found to have no significant impact on RI (hazards ratio, 1.29; 95% confidence interval, 0.84-1.97 [P = .24]) or leukemia-free survival (hazards ratio, 1.00; 95% confidence interval, 0.71-1.42 [P = .99])., Conclusions: The data from the current study suggest no apparent advantage for postremission consolidation chemotherapy before RIC alloSCT, provided a donor is readily available., (© 2013 American Cancer Society.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results